Published in ACS Appl Mater Interfaces on January 10, 2017
Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (1970) 1528.65
Ultra-large-scale syntheses of monodisperse nanocrystals. Nat Mater (2004) 6.19
Superparamagnetic iron oxide contrast agents: physicochemical characteristics and applications in MR imaging. Eur Radiol (2001) 4.84
Recent advances in iron oxide nanocrystal technology for medical imaging. Adv Drug Deliv Rev (2006) 4.69
Synthesis of highly crystalline and monodisperse maghemite nanocrystallites without a size-selection process. J Am Chem Soc (2001) 4.28
Superparamagnetic iron oxide nanoparticle probes for molecular imaging. Ann Biomed Eng (2006) 3.67
Active targeting schemes for nanoparticle systems in cancer therapeutics. Adv Drug Deliv Rev (2008) 2.87
Colorimetric ferrozine-based assay for the quantitation of iron in cultured cells. Anal Biochem (2004) 2.75
Magnetic nanoparticles: design and characterization, toxicity and biocompatibility, pharmaceutical and biomedical applications. Chem Rev (2012) 2.26
Multifunctional nanostructured materials for multimodal imaging, and simultaneous imaging and therapy. Chem Soc Rev (2008) 2.25
Superparamagnetic iron oxide based MRI contrast agents: Current status of clinical application. Quant Imaging Med Surg (2011) 2.07
Ferucarbotran (Resovist): a new clinically approved RES-specific contrast agent for contrast-enhanced MRI of the liver: properties, clinical development, and applications. Eur Radiol (2002) 2.06
Ultrastable iron oxide nanoparticle colloidal suspensions using dispersants with catechol-derived anchor groups. Nano Lett (2009) 1.85
On T(2)-shortening by strongly magnetized spheres: a partial refocusing model. Magn Reson Med (2002) 1.62
On T2-shortening by weakly magnetized particles: the chemical exchange model. Magn Reson Med (2001) 1.61
COMU: a safer and more effective replacement for benzotriazole-based uronium coupling reagents. Chemistry (2009) 1.34
Prostate cancer: detection of lymph node metastases outside the routine surgical area with ferumoxtran-10-enhanced MR imaging. Radiology (2009) 1.34
Stabilization and functionalization of iron oxide nanoparticles for biomedical applications. Nanoscale (2011) 1.31
Magnetite Nanoparticles for Medical MR Imaging. Mater Today (Kidlington) (2011) 1.26
Contrast-enhanced MR imaging of liver and spleen: first experience in humans with a new superparamagnetic iron oxide. J Magn Reson Imaging (1995) 1.25
Chemical design of biocompatible iron oxide nanoparticles for medical applications. Small (2012) 1.16
Magnetic resonance of a dextran-coated magnetic fluid intravenously administered in mice. Biophys J (2001) 1.14
Applications and potential toxicity of magnetic iron oxide nanoparticles. Small (2012) 1.12
Axillary lymph node metastases in patients with breast carcinomas: assessment with nonenhanced versus uspio-enhanced MR imaging. Radiology (2006) 1.09
Compact zwitterion-coated iron oxide nanoparticles for biological applications. Nano Lett (2011) 1.06
Relaxivity optimization of a PEGylated iron-oxide-based negative magnetic resonance contrast agent for T₂-weighted spin-echo imaging. ACS Nano (2012) 1.05
Clusters of superparamagnetic iron oxide nanoparticles encapsulated in a hydrogel: a particle architecture generating a synergistic enhancement of the T2 relaxation. ACS Nano (2011) 1.02
The effect of static magnetic fields on the aggregation and cytotoxicity of magnetic nanoparticles. Biomaterials (2011) 0.97
Pebbles and PebbleJuggler: software for accurate, unbiased, and fast measurement and analysis of nanoparticle morphology from transmission electron microscopy (TEM) micrographs. Nanoscale (2012) 0.97
Surface functionalization of single superparamagnetic iron oxide nanoparticles for targeted magnetic resonance imaging. Small (2009) 0.96
Superparamagnetic iron oxide nanoparticles for MRI: contrast media pharmaceutical company R&D perspective. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2013) 0.89
Surface design of core-shell superparamagnetic iron oxide nanoparticles drives record relaxivity values in functional MRI contrast agents. Chem Commun (Camb) (2012) 0.86
Complete Exchange of the Hydrophobic Dispersant Shell on Monodisperse Superparamagnetic Iron Oxide Nanoparticles. Langmuir (2015) 0.84
Current status of superparamagnetic iron oxide contrast agents for liver magnetic resonance imaging. World J Gastroenterol (2015) 0.83
Highly stable monodisperse PEGylated iron oxide nanoparticle aqueous suspensions: a nontoxic tracer for homogeneous magnetic bioassays. Nanoscale (2013) 0.83
Surface functionalization of nanoparticles to control cell interactions and drug release. Small (2012) 0.83
Melt-grafting for the synthesis of core-shell nanoparticles with ultra-high dispersant density. Nanoscale (2015) 0.83
Core-Shell Structure of Monodisperse Poly(ethylene glycol)-Grafted Iron Oxide Nanoparticles Studied by Small-Angle X-ray Scattering. Chem Mater (2015) 0.81
Enhancement and degradation of the R2* relaxation rate resulting from the encapsulation of magnetic particles with hydrophilic coatings. Magn Reson Med (2011) 0.81
Effect of PEG molecular weight on stability, T₂ contrast, cytotoxicity, and cellular uptake of superparamagnetic iron oxide nanoparticles (SPIONs). Colloids Surf B Biointerfaces (2014) 0.81
Design of a multi-dopamine-modified polymer ligand optimally suited for interfacing magnetic nanoparticles with biological systems. Langmuir (2014) 0.79
Cationic surface modification of gold nanoparticles for enhanced cellular uptake and X-ray radiation therapy. J Mater Chem B Mater Biol Med (2015) 0.77
Surface-charge differentiation of streptavidin and avidin by atomic force microscopy-force spectroscopy. Chemphyschem (2014) 0.76
Evaluation of High-Yield Purification Methods on Monodisperse PEG-Grafted Iron Oxide Nanoparticles. Langmuir (2016) 0.76
Magnetic decoupling of surface Fe3+ in magnetite nanoparticles upon nitrocatechol-anchored dispersant binding. Chemistry (2011) 0.76